Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders

 
 

Denali Therapeutics Inc. (DNLI) Add to portfolio

Denali Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing therapeutics for neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis.

Sector: Healthcare
Industry: Biotechnology

CEO: Ryan J. Watts
https://www.denalitherapeutics.com

Recent News + Filings   (All items)

Financial Summary   (All financials)
In millions, except per share itemsDec-31-16Dec-31-15
Revenues75.711.6
            Revenue growth554.2% 
Cost of goods sold87.416.7
Gross profit-11.7-5.1
            Gross margin-15.5%-44.1%
General and administrative11.75.1
EBIT-87.4-16.7
            EBIT margin-115.5%-144.1%
Pre-tax income-86.7-16.8
Income taxes0.00.0
            Tax rate0.0%0.0%
Net income-86.7-16.8
            Net margin-114.5%-145.1%
 
Diluted EPS($13.49)($5.58)
Shares outstanding (diluted)6.43.0
 
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.

Rocket Data Systems, Inc. © 2018 | Contact Us | Data Disclaimer | Terms of Use | Privacy